Welcome to our dedicated page for Amicus Therapeut news (Ticker: FOLD), a resource for investors and traders seeking the latest updates and insights on Amicus Therapeut stock.
Amicus Therapeutics Inc (FOLD) is a biotechnology leader developing innovative therapies for rare metabolic diseases. This dedicated news hub provides investors and healthcare stakeholders with essential updates on clinical advancements, regulatory milestones, and corporate developments.
Key resources include earnings reports, FDA submission announcements, research publications, and partnership disclosures. Our curated collection enables informed decision-making by tracking material events across the company's lysosomal storage disorder pipeline, including Fabry and Pompe disease programs.
Bookmark this page to efficiently monitor Amicus Therapeutics' progress in advancing precision medicines through clinical trials and commercialization efforts. Regular updates ensure you never miss critical developments in this dynamic biotech sector.
Amicus Therapeutics (Nasdaq: FOLD) announced that its management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL, on June 11, 2024, at 4:00 p.m. E.T.
The live audio webcast of the presentation will be accessible via the investors section of the Amicus Therapeutics website. Amicus Therapeutics is a biotechnology firm focused on developing medicines for rare diseases, committed to advancing a pipeline of innovative treatments.
Amicus Therapeutics (Nasdaq: FOLD) announced that its two-component therapy, Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat), has won the 2024 Prix Galien U.K. Award for Best Pharmaceutical Product. This prestigious award celebrates outstanding advances in the discovery and development of innovative products that improve human health. Pombiliti + Opfolda is the first and only therapy for eligible adults with late-onset Pompe disease, a debilitating lysosomal disorder. The award underscores the dedication of Amicus Therapeutics and the broader Pompe community in addressing this rare disease. The Galien Foundation, responsible for these awards, is committed to fostering innovation in medical science.
Amicus Therapeutics reported a total revenue of $110.4M for 1Q 2024, showing a 28% increase year-over-year. They raised their full-year 2024 revenue growth guidance to 25%-30%. Galafold sales increased by 15%, with Pombiliti + Opfolda sales growing by 30%. Non-GAAP profitability is projected for 2024. The company aims to achieve double-digit Galafold revenue growth and launch Pombiliti + Opfolda successfully.
Amicus Therapeutics will participate in the Bank of America 2024 Health Care Conference in Las Vegas. The company aims to present its dedication to developing medicines for rare diseases. The event will feature a fireside chat with management on May 15, 2024, at 1:40 p.m. P.T.
Amicus Therapeutics (Nasdaq: FOLD) will announce its first-quarter 2024 financial results on May 9, 2024. A conference call and live webcast will be held to discuss the results. The company is a global biotechnology firm focused on developing medicines for rare diseases.
FAQ
What is the current stock price of Amicus Therapeut (FOLD)?
What is the market cap of Amicus Therapeut (FOLD)?
